Structure Therapeutics (NASDAQ:GPCR) Shares Up 8% Following Earnings Beat

Structure Therapeutics Inc. (NASDAQ:GPCR) shares traded up 8% during trading on Thursday following a better than expected earnings announcement. The stock traded as high as $21.07 and last traded at $21.48. 527,092 shares traded hands during trading, a decline of 31% from the average session volume of 768,022 shares. The stock had previously closed at $19.88.

The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. William Blair assumed coverage on Structure Therapeutics in a research report on Friday. They issued an “outperform” rating on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $91.00 target price on shares of Structure Therapeutics in a research report on Wednesday, December 18th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of Structure Therapeutics in a research report on Thursday, December 19th. Finally, Stifel Nicolaus started coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price target for the company. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, Structure Therapeutics has an average rating of “Buy” and an average target price of $81.29.

Institutional Investors Weigh In On Structure Therapeutics

Institutional investors have recently made changes to their positions in the stock. ANTIPODES PARTNERS Ltd lifted its stake in Structure Therapeutics by 115.0% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock worth $28,000 after purchasing an additional 553 shares during the last quarter. GAMMA Investing LLC lifted its stake in Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock worth $31,000 after purchasing an additional 1,122 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in Structure Therapeutics during the fourth quarter worth $34,000. FNY Investment Advisers LLC bought a new stake in Structure Therapeutics during the fourth quarter worth $40,000. Finally, Assetmark Inc. lifted its stake in Structure Therapeutics by 120.0% during the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after purchasing an additional 719 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Stock Up 4.1 %

The firm has a 50 day simple moving average of $26.58 and a two-hundred day simple moving average of $33.59. The stock has a market capitalization of $1.36 billion, a P/E ratio of -32.09 and a beta of -2.75.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.